R&G PHARMASTUDIES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.03 CNY | -2.16% |
|
-9.53% | -31.72% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With a 2024 P/E ratio at 24.6 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -31.72% | 597M | - | - | |
| -28.75% | 70.3B | B- | ||
| +2.04% | 27.46B | C+ | ||
| -6.19% | 17.8B | B | ||
| +2.32% | 17.46B | A- | ||
| +2.10% | 15.46B | A- | ||
| +7.06% | 13.49B | B- | ||
| +10.80% | 13.06B | A- | ||
| +71.31% | 12.96B | C- | ||
| +75.96% | 12.56B | C+ |
Investor Rating
-
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 301333 Stock
- Ratings R&G PharmaStudies Co., Ltd.
